Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings

Core Viewpoint - Thermo Fisher Scientific Inc. is expected to report its third-quarter 2024 results on October 23, with mixed expectations for revenue and earnings performance compared to the previous year [1][2]. Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for Thermo Fisher's Q3 revenues is $10.64 billion, reflecting a 0.6% increase from the same quarter last year [2]. - The consensus estimate for earnings is $5.25 per share, indicating a 7.7% decline from the year-ago quarter [2]. - Earnings estimates have decreased by 0.6% in the past 30 days [3]. Group 2: Segment Performance Insights - The Analytical Instruments segment is anticipated to show strong sales growth, with projected revenues of $1.9 billion, representing a 12.7% year-over-year increase, driven by new product launches [5]. - The Life-Science Solutions segment is expected to generate $2.5 billion in revenues, marking a 2% improvement year over year, aided by the acquisition of Olink Holding AB [8]. - The Specialty Diagnostics segment is projected to report $1 billion in revenues, suggesting a 3.1% decline year over year, despite positive contributions from transplant diagnostics and immunodiagnostics [11]. Group 3: Recent Developments and Innovations - The company launched several new products, including the Thermo Scientific Stellar Mass Spectrometer and new editions of the ThermoScientific Orbitrap Ascend Tribrid Mass Spectrometer, which are expected to enhance revenue [4][5]. - A new bio-based film for single-use technologies was introduced, contributing to growth in the bioproduction business [7]. - Recent partnerships and product launches, such as the CorEvitas Adolescent Atopic Dermatitis Registry and the myeloMATCH trial with the National Cancer Institute, are expected to positively impact the company's performance [9][10]. Group 4: Operational Expansion - Thermo Fisher opened a new electron microscopy demo center in Taiwan and expanded its global laboratory services with a new bioanalytical lab in Sweden, which may favorably influence revenue [12][13].